Antipsychotic Roundup 2009

March, 2009 | Vol: 7 Issue: 3

In this issue

Learning Objective

Learning Objectives, March 2009

This CME/CE activity is intended for psychiatrists, psychiatric nurses, psychologists and other health care professionals with an interest in the diagnosis and treatment of psychiatric disorders.


Atypicals for Non-psychotic disorders

You may have noticed a recent torrent of FDA approvals and clinical trials for atypical antipsychotics in every disorder under the sun–except psychosis. Is this simply an effort by the sponsoring companies to get us to prescribe more antipsychotics? Or are these drugs truly effective for non-psychotic disorders? What’s the quality of the evidence?

Prescribing Atypical Antipsychotics: What are the Risks?

Over the past several years, the use of antipsychotics has expanded dramatically. Aside from the traditional indication, schizophrenia, various members of this class have received FDA approval for bipolar mania, bipolar depression, major depression, and autism, and increasingly they are used off-label for anxiety, insomnia, and agitation. As with any type of medication that becomes popular quickly, unforeseen side effects have emerged, some minor, others serious. In this article we will briefly review some of the more serious potential risks.

Research Update

Expert QA